Delcath's CHEMOSAT System Recommended in ESMO-EURACAN Uveal Melanoma Guidelines
Event summary
- Delcath's CHEMOSAT Hepatic Delivery System for Melphalan (M-PHP) included as a recommended liver-directed therapy in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma (April 2026).
- M-PHP recognized for improved hepatic and overall progression-free survival in Phase 3 trials, with an ESMO-Magnitude of Clinical Benefit Scale score of 3.
- Guideline positions M-PHP as a first-line regional treatment option for patients with multifocal liver-only metastases, either as monotherapy or in combination with systemic treatments.
- HEPZATO KIT (melphalan/HDS) listed as a Category 2A recommended treatment in NCCN guidelines for metastatic uveal melanoma.
The big picture
Delcath's inclusion in the ESMO-EURACAN guidelines solidifies M-PHP as a standard liver-directed therapy for uveal melanoma in Europe, complementing its existing NCCN recognition in the U.S. The endorsement underscores the growing role of regional therapies in multidisciplinary cancer care, particularly for patients with liver-dominant disease. With up to 90% of uveal melanoma patients developing liver metastases, this validation could expand Delcath's market reach in a niche but critical oncology segment.
What we're watching
- Adoption Dynamics
- The pace at which European medical centers integrate M-PHP into treatment protocols for uveal melanoma patients.
- Clinical Validation
- Whether the ESMO-EURACAN endorsement accelerates real-world evidence supporting M-PHP's long-term efficacy.
- Competitive Positioning
- How Delcath differentiates M-PHP against emerging systemic therapies like tebentafusp and anti-PD-1 immunotherapy.
Related topics